Harley Davidson OPTIMISM and 4 Analyst Notes Making Rounds Now
Navistar International Corp. (NYSE:NAV): According to Jefferies, Navistar shares are in the end worth a ranking in the mid-$40s at least, and are an intriguing value at present levels. Jefferies thinks that attaining engine certification is still the key to near-term earnings and maintains a Buy rating on Navistar with a $45 price target.
Don’t Miss: Here are the STUDS and DUDS of the DOW for 2012.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Affymax (NASDAQ:AFFY), Theravance (NASDAQ:THRX) and Rigel Pharmaceuticals (NASDAQ:RIGL) have been featured by Piper Jaffray as possible takeout candidates in the biotech arena after Bristol-Myers’ (NYSE:GMY) acquisition of Amylin. Piper Jaffray thinks the takeover of BioMarin could be priced at $79 per share, and reports Takeda might be the most likely suitor for Affymax.
F5 Networks, Inc. (NASDAQ:FFIV): Following conducting checks, Oppenheimer thinks F5 might turn in lesser than hoped results for its September quarter. The firm lowered its target on the stock from $150 to $130 but holds to an Outperform rating on the shares.
Harley-Davidson, Inc. (NYSE:HOG): RBC Capital, after conducting checks, thinks Harley-Davidson’s sales might have climbed by double-digits in the past month. The firm believes estimates for Harley-Davidson might not grow, but the stock’s multiple might grow, and RBC sticks to an Outperform rating on the shares.
Medgenics Inc (MDGN): More upside is probable for shares of Medgenics, according to Maxim, which repeats its Buy rating on the stock with an increased price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.